Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00452582 · ClinicalTrials.gov registry record · Phase 1
Sildenafil (Viagra) Treatment of Subacute Ischemic Stroke
A Phase 1 study, sponsored by Henry Ford Health System.
- Terminated
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT00452582 is a Phase 1 study that was terminated before completion, run by Henry Ford Health System. The registered enrollment target is 20 participants.
The verdict
NCT00452582, a Phase 1 study, was terminated before completion, sponsored by Henry Ford Health System.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
Stroke is the third leading cause of death in the United States and the leading cause of serious long-term disability. Approximately 50% of the 750,000 people affected by stroke each year have residual physical impairment. Treatment options for recovery are limited at this time. Sildenafil (Viagra) has demonstrated the capability of significantly improving recovery in several animal experiments of stroke. This study is aiming to establish the safety of treatment with sildenafil in people with stroke with the ultimate aim of testing its usefulness to improve recovery.
Interventions
- OTHER Usual care
- DRUG Sildenafil (Viagra)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2005-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00452582
The ClinicalTrials.gov registry entry for NCT00452582 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Henry Ford Health System, which has 234 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Usual care is the first listed.
NCT00452582 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00452582 about?
NCT00452582 is a clinical study titled "Sildenafil (Viagra) Treatment of Subacute Ischemic Stroke". Stroke is the third leading cause of death in the United States and the leading cause of serious long-term disability. Approximately 50% of the 750,000 people affected by stroke each year have residual physical impairment. Treatment options for recovery are limited at this time. Sildenafil (Viagra) ...
What is the current status of trial NCT00452582?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2005-04.
What interventions are being tested in trial NCT00452582?
The interventions under investigation include: Usual care (OTHER), Sildenafil (Viagra) (DRUG).
Who is sponsoring clinical trial NCT00452582?
This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.